Patient Payment Responsibility up 13% in One Year CHICAGO,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Patient Payment Responsibility up 13% in One Year

CHICAGO, IL --(Marketwired - June 28, 2016) - A new TransUnion Healthcare ( NYSE : TRU ) analysis found that patients continue to face an increased financial burden as their healthcare costs rise and revolving credit lines decline. TransUnion's latest Healthcare Report was released today at the 2016 Healthcare Financial Management Association's Annual National Institute in Las Vegas.

The Healthcare Report demonstrated how payment responsibility for medical costs continues to shift from employers to patients. Between 2014 and 2015, patients experienced a 13% increase in both deductible and out-of-pocket maximum costs. The average deductible for consumers in 2015 was $1,278 while out-of-pocket costs rose to $3,470. Medical procedures with the highest out-of-pocket costs for patients, included: Dermatology ($2,451), Orthopedics ($2,405) and General Surgery ($2,264).

"It's clear that patients are becoming the new payer -- a major source for payments to hospitals at both the time of service and after procedures," said Jonathan Wiik, principal for revenue cycle management at TransUnion Healthcare. "As hospitals navigate this new era of patient payments, we expect to see them provide more financing options to help patients meet their financial obligations. Healthcare providers also will evaluate resources, such as a patient's propensity to pay, and engage with patients much earlier regarding financial discussions to ensure the patient is well educated to the cost of their care. This will help the patient keep their focus on getting better versus the worry about paying a large bill."

Higher medical costs are likely impacting how consumers pay their medical bills. As of Q1 2016, approximately 51% of patients owe more than $1000 to their healthcare providers. Nearly eight in 10 patients (77%) owe more than $500.

TransUnion Healthcare's proprietary ratio comparing available revolving credit to select healthcare costs reinforces this, as the ratio declined to 17.2 to 1 in Q1 2016. The ratio means that for every $100 in healthcare costs, consumers had $1,720 in revolving credit to potentially make those payments at the end of March 2016. Just one year prior, consumers had $2,250 in revolving credit for medical costs as the ratio stood at 22.5 to 1 in Q1 2015.

TransUnion's analysis found that patients in the subprime risk tier, generally the highest-risk consumers with a VantageScore 3.0 of 600 or below, are in an even more perilous position. As of Q1 2016, these patients only had $420 in revolving credit for every $100 in healthcare costs. In Q1 2015, these same patients had $600.

TransUnion Healthcare Cost Ratio (Q1 2014 - Q1 2016) For Every $100 in Healthcare Costs, Consumers Had the Following Revolving Credit to Potentially Make Those Payments

Consumers/Year   Q1 2014   Q1 2015   Q1 2016
All Consumers   $2,310   $2,250   $1,720
Subprime Consumers   $660   $600   $420

"Our findings emphatically demonstrate that despite the advent of the Affordable Care Act, more patients are struggling to pay their healthcare costs," said Gerry McCarthy, president of TransUnion Healthcare. "In fact, patient payment responsibility continues to rise even as they have less available credit to make their healthcare payments. It's a precarious position for consumers and healthcare providers alike, but fortunately many hospitals are beginning to implement new technologies that can help alleviate some of these issues now and in the future."

With millions of dollars of unpaid medical bills, many hospitals are instituting new processes to recover monies owed to them. TransUnion Healthcare's insurance discovery solution, eScan, has helped hospitals, health systems and physician offices recover more than $1.2 billion in insurance payments. Previously, hospitals would have categorized this money as bad debt or charity care, which are known as uncompensated care. "An indication that healthcare providers are beginning to implement new, innovative processes to receive healthcare payments can be observed by the fact that $700 million of the $1.2 billon recovered dollars has occurred in just the last three years," added McCarthy.

Transunion Healthcare also is working with hospitals to stratify their bad debt portfolio through its Financial Clearinghouse suite of solutions, which determine charity eligibility, ability (propensity) to pay, as well as community or full credit analyses.

"Employing these solutions at the front of the revenue cycle is an industry best practice," said Wiik. "Given the increased payment risk to providers and the dilution of available credit, differentiating between a patients' ability versus willingness to pay will become increasingly important for hospitals. Having processes and tools in place to establish funding mechanisms will benefit the patient and provider."

The TransUnion Healthcare Report includes anonymous data estimates from thousands of providers, including hospitals and healthcare clinics from across the nation. The data points focus on patient payment responsibilities for key, commonly administered procedures. That information was, in turn, compared with financial data gathered from TransUnion's proprietary Industry Insights Report, powered by Prama℠ analytics. The TransUnion Healthcare Report looks at available revolving credit as an indicator for how consumers might cover out-of-pocket medical costs.

For more information about the TransUnion Healthcare Report, please visit http://www.transunioninsights.com/studies/healthcare . Attendees of the 2016 HFMA ANI can learn more about TransUnion Healthcare at Booth #830.

About TransUnion Healthcare TransUnion Healthcare, a wholly owned subsidiary of credit and information management company TransUnion, empowers providers with Intelligence in an Instant ® by providing data and analytics at the point of need. TransUnion offers a series of data solutions designed to provide greater ease of use, accuracy and transparency in the revenue cycle process thereby assisting providers in lowering their uncompensated care. TransUnion Healthcare was recently rated the highest performing vendor by the KLAS 2014 Patient Access Report for its patient payment estimation and propensity to pay solutions. www.transunionhealthcare.com

About TransUnion ( NYSE : TRU )

Information is a powerful thing. At TransUnion, we realize that. We are dedicated to finding innovative ways information can be used to help individuals make better and smarter decisions. We help uncover unique stories, trends and insights behind each data point, using historical information as well as alternative data sources. This allows a variety of markets and businesses to better manage risk and consumers to better manage their credit, personal information and identity. Today, TransUnion has a global presence in more than 30 countries and a leading presence in several international markets across North America, Africa, Latin America and Asia. Through the power of information, TransUnion is working to build stronger economies and families and safer communities worldwide.

We call this Information for Good. http://www.transunion.com/business

Contact Dave Blumberg TransUnion dblumberg@transunion.com 312-972-6646

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 363

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 387

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 544

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 109

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 305

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 161

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 411

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 174

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 277

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Breakthroughs in Lung Cancer Treatment with Reqorsa

Updated Category News Views 182

Innovative Advances in Lung Cancer Treatment The fight against lung cancer continues to evolve, showcasing promising advancements that bring new hope to patients. Genprex, Inc. is at the forefront of this battle with its revolutionary gene therapy known as Reqorsa. This cutting-edge treatment has been developed specifically to target KRAS mutation in non-small cell lung...

Continue Reading
EfTEN United Property Fund Reports October Earnings and NAV

Updated Category News Views 192

Insights into EfTEN United Property Fund's Recent Performance EfTEN United Property Fund demonstrated a net profit of 110 thousand euros for October, totaling 2.214 million euros for the first ten months of the year, marking a significant improvement from 724 thousand euros during the same period last year. This impressive financial outcome led to a distribution to...

Continue Reading
Cardiff Oncology Reports Encouraging Results in mCRC Trial

Updated Category News Views 236

Cardiff Oncology Reveals Promising Clinical Trial Results Cardiff Oncology, Inc. (Nasdaq: CRDF), a pioneering clinical-stage biotechnology company, has recently announced encouraging results from its ongoing CRDF-004 clinical trial. This randomized Phase 2 trial is investigating the effects of onvansertib in patients suffering from first-line RAS-mutated metastatic...

Continue Reading
Japan's Growing Casting Polyurethane Market and Its Future

Updated Category News Views 127

Japan's Casting Polyurethane Market: A Rising Force The Japan casting polyurethane market is on the verge of significant transformation, anticipated to elevate from a valuation of US$ 134.74 million to a remarkable US$ 248.24 million by 2033. This growth trajectory highlights a compelling compound annual growth rate (CAGR) of 7.08%, revealing the underlying strength...

Continue Reading
Hudson Technologies Faces Challenges Amid Downgrade by B.Riley

Updated Category News Views 353

B.Riley Downgrades Hudson Technologies Stock In a recent market statement, B.Riley has lowered its outlook on Hudson Technologies (NASDAQ: HDSN), shifting the stock rating from Buy to Neutral. This adjustment comes amidst new growth projections adjusted downwards from +16.6% to +8.5%. The modification in expectations has been linked to ongoing pressures on...

Continue Reading